HK1152474A1 - Methods and compositions for the prevention and treatment of sepsis - Google Patents

Methods and compositions for the prevention and treatment of sepsis

Info

Publication number
HK1152474A1
HK1152474A1 HK11106525.8A HK11106525A HK1152474A1 HK 1152474 A1 HK1152474 A1 HK 1152474A1 HK 11106525 A HK11106525 A HK 11106525A HK 1152474 A1 HK1152474 A1 HK 1152474A1
Authority
HK
Hong Kong
Prior art keywords
sepsis
prevention
compositions
treatment
methods
Prior art date
Application number
HK11106525.8A
Other languages
English (en)
Chinese (zh)
Inventor
Sek Chung Fung
Tom Eirik Mollnes
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1152474A1 publication Critical patent/HK1152474A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK11106525.8A 2003-05-15 2011-06-23 Methods and compositions for the prevention and treatment of sepsis HK1152474A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47068103P 2003-05-15 2003-05-15

Publications (1)

Publication Number Publication Date
HK1152474A1 true HK1152474A1 (en) 2012-03-02

Family

ID=33476736

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11106525.8A HK1152474A1 (en) 2003-05-15 2011-06-23 Methods and compositions for the prevention and treatment of sepsis

Country Status (11)

Country Link
US (1) US8329169B2 (fr)
EP (2) EP2266606B1 (fr)
JP (2) JP4768620B2 (fr)
CN (2) CN102258784A (fr)
AU (2) AU2004241069B2 (fr)
CA (1) CA2524534C (fr)
DK (1) DK1628530T3 (fr)
ES (2) ES2387275T3 (fr)
HK (1) HK1152474A1 (fr)
MX (1) MXPA05011886A (fr)
WO (1) WO2004103294A2 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007001332A2 (fr) * 2004-08-04 2007-01-04 University Of Massachusetts Immunoadhesines anti-pathogene
EP1819731A4 (fr) * 2004-12-08 2013-02-13 Immunomedics Inc Procedes et compositions pour l'immunotherapie et la detection de maladies inflammatoires et de dereglement immunitaire, de maladies infectieuses, d'angiogeneses pathologiques et de cancers
US20100263061A1 (en) * 2007-06-11 2010-10-14 The Trustees Of The University Of Pennsylvania Properdin Modulation of Alternative Pathway and Uses Thereof
EP2278987A4 (fr) * 2008-03-28 2012-08-22 Apellis Ag Modulation et réplétion/amélioration du système complémentaire dans le traitement des traumatismes
US9291622B2 (en) 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
WO2010151526A1 (fr) 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Anticorps bispécifiques se liant aux protéines du complément
EP2309001A1 (fr) * 2009-09-23 2011-04-13 SIRS-Lab GmbH Procédé de détermination et de différenciation in vitro d'états physiopathologiques
WO2011106635A1 (fr) * 2010-02-25 2011-09-01 The Trustees Of The University Of Pennsylvania Traitement de la sepsie utilisant des inhibiteurs du complément
AU2011224224B2 (en) * 2010-03-10 2015-07-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
SG185383A1 (en) 2010-04-30 2012-12-28 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
US9120838B2 (en) 2011-04-18 2015-09-01 Curators Of The University Of Missouri Saccharide conjugates
EP2708233B1 (fr) 2011-05-13 2018-06-27 The University of Tokyo Ctrp6 qui peut être utilisée à titre d'agent thérapeutique et prophylactique pour les maladies auto-immunes
CN103649756B (zh) * 2011-05-19 2016-07-06 持田制药株式会社 使用血液样本的呼吸道传染病的诊断
ES2701075T3 (es) 2011-07-01 2019-02-20 Univ Pennsylvania Anticuerpos antiproperdina y usos de estos
CN102363781A (zh) * 2011-10-19 2012-02-29 海南大学 一种有效抑制小鼠mCD14基因表达的小干扰核糖核酸分子
CN102533758B (zh) * 2011-10-19 2014-04-02 海南大学 一种抑制水牛膜分化抗原14 基因表达的小核糖核酸分子
CA2859493A1 (fr) 2011-12-21 2013-06-27 Novartis Ag Compositions et procedes pour des anticorps ciblant le facteur p
EP2912065A4 (fr) 2012-10-25 2016-10-19 True North Therapeutics Inc Anticorps de la c1s anti-complément et leurs utilisations
PT2914291T (pt) 2012-11-02 2022-05-05 Bioverativ Usa Inc Anticorpos anti-complemento c1s e suas utilizações
US20160090425A1 (en) * 2013-05-15 2016-03-31 Annexon, Inc. Anti-complement factor c1s antibodies and uses thereof
SG10201710758PA (en) 2013-07-09 2018-02-27 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
AU2014306002B2 (en) * 2013-08-07 2017-05-25 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
WO2015054569A1 (fr) * 2013-10-10 2015-04-16 Viropharma Holdings Limited Procédés d'inhibition de la voie alternative d'activation du système immunitaire complémentaire et compositions utilisées dans ces procédés
US20160289270A1 (en) * 2013-11-18 2016-10-06 Westfaelische Wilhelms-Universitaet Muenster Methods, Peptides and Antibodies for Preventing, Treating and Diagnosing an Inflammatory Condition
US20170107294A1 (en) * 2014-03-21 2017-04-20 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
BR112016029076B1 (pt) 2014-06-12 2024-02-15 Ra Pharmaceuticals, Inc Polipeptídeo e composição compreendendo o mesmo para inibir a clivagem de c5 em um sistema celular
US10316081B2 (en) 2014-11-05 2019-06-11 Annexon, Inc. Humanized anti-complement factor C1Q antibodies
US20160168237A1 (en) * 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
PL3250230T3 (pl) 2015-01-28 2022-02-14 Ra Pharmaceuticals, Inc. Modulatory aktywności dopełniacza
HRP20230093T1 (hr) 2015-04-06 2023-03-31 Bioverativ Usa Inc. Humanizirana anti-c1s protutijela i postupci njihove primjene
WO2017075189A1 (fr) 2015-10-27 2017-05-04 University Of Massachusetts Immunothérapie utilisant le fragment fc du facteur h
BR112018010360A2 (pt) 2015-11-24 2018-12-04 Annexon Inc fragmentos fab de fator de complemento anti-c1q e utilizações dos mesmos
LT3389692T (lt) 2015-12-16 2020-04-27 Ra Pharmaceuticals, Inc. Komplemento aktyvumo moduliatoriai
WO2017134043A1 (fr) * 2016-02-01 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et composition pharmaceutique pour la neutralisation de l'activité cytotoxique des protéines histones extracellulaires chez les patient souffrant de sepsie
BR112019011053A2 (pt) 2016-12-07 2019-10-15 Ra Pharmaceuticals Inc moduladores da atividade do complemento
BR112020010916A2 (pt) 2017-12-04 2020-11-17 Ra Pharmaceuticals, Inc moduladores da atividade do complemento
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
WO2020011869A2 (fr) 2018-07-11 2020-01-16 Roche Innovation Center Copenhagen A/S Oligonucléotides antisens ciblant tlr2
EP3934675A2 (fr) 2019-03-08 2022-01-12 RA Pharmaceuticals, Inc. Modulateurs d'activité du complément
WO2020205501A1 (fr) 2019-03-29 2020-10-08 Ra Pharmaceuticals, Inc. Modulateurs du complément et procédés associés
US20220211799A1 (en) 2019-04-24 2022-07-07 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP2703764B2 (ja) * 1986-04-28 1998-01-26 シータス オンコロジー コーポレイション 補体成分Ｃ５ａに対するモノクローナル抗体
US5093117A (en) 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
AU645515B2 (en) * 1989-08-01 1994-01-20 Rockefeller University, The Methods and compositions for ameliorating the symptoms of sepsis
US6315999B1 (en) 1989-08-10 2001-11-13 Solvay, S.A. Pharmaceutical product for the treatment of sepsis
DE4029227A1 (de) 1990-09-14 1992-03-19 Imtox Gmbh Arzneimittel enthaltend cd14
WO1993006726A1 (fr) 1991-09-30 1993-04-15 Mackenzie Walser Procedes de traitement des lesions tissulaires induites par des radicaux libres
EP0634935A4 (fr) 1992-04-06 1996-01-31 North Shore Univ Hospital Nouvelle therapie permettant de traiter la septicemie a l'aide d'une forme soluble de l'antigene myelomonocytique cd14 recombine.
US6063764A (en) 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US5330754A (en) * 1992-06-29 1994-07-19 Archana Kapoor Membrane-associated immunogens of mycobacteria
CA2155933C (fr) * 1993-02-12 2000-04-04 James L. Levin Administration pulmonaire de scr1 et d'autres proteines inhibitrices du complement
WO1994028025A1 (fr) 1993-05-28 1994-12-08 The Scripps Research Institute Procedes et compositions d'inhibition de l'activation des cellules induites par cd14
JPH10502249A (ja) * 1994-07-05 1998-03-03 スティーノ・リサーチ・グループ・アクティーゼルスカブ 免疫調節剤
ES2255708T3 (es) 1994-09-16 2006-07-01 The Scripps Research Institute Uso de anticuerpos para bloquear los efectos de las bacterias gram-positivas y las micobacterias.
PL320922A1 (en) * 1994-12-23 1997-11-10 Om Lab Sa Application of mhc-ii bonding and/or somulating molecules in prevention and/or treatment of diseases involving inflammatory processes
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6042821A (en) 1995-11-21 2000-03-28 Smithkline Beecham Corporation Method of treating sepsis with chemokines
US6290948B1 (en) 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
KR20000015895A (ko) * 1996-05-22 2000-03-15 유니버시티 오브 알버타 타입-2 케모카인 결합 단백질 및 그 이용방법
WO1998017312A1 (fr) 1996-10-22 1998-04-30 Chugai Seiyaku Kabushiki Kaisha Remede contre les troubles septiques et comprenant un anticorps anti-il-8 en qualite d'ingredient actif
US6172220B1 (en) 1997-01-21 2001-01-09 Board Of Regents Of University Of Nebraska Isolated algal lipopolysaccharides and use of same to inhibit endotoxin-initiated sepsis
US6251873B1 (en) 1997-03-07 2001-06-26 Mochida Pharmaceutical Co., Ltd. Antisense compounds to CD14
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
ID26730A (id) 1998-05-27 2001-02-01 Gemma Biotechnology Ltd Induksi protein-protein dan peptida-peptida antibiotik oleh lait/scd14-protein
IL142017A0 (en) * 1998-09-24 2002-03-10 Univ Minnesota Human complement c3-degrading polypeptide from streptococcus pneumoniae
CA2347250A1 (fr) * 1998-10-22 2000-04-27 Sau-Chi Betty Yan Methodes de traitement de la septicemie
US20030114377A1 (en) 1998-11-18 2003-06-19 Kirkland Theo N. Inhibition therapy for septic shock with mutant CD14
DE19913707A1 (de) 1999-03-26 2000-10-05 Privates Inst Bioserv Gmbh Immunadsorber zur Sepsistherapie
SK14232001A3 (sk) * 1999-04-09 2002-06-04 Basf Aktiengesellschaft Nízkomolekulové inhibítory komplementárnych proteáz
ES2250132T3 (es) * 1999-05-18 2006-04-16 Teijin Limited Remedios preventivos para enfermedades asociadas a quimioquinas.
US6673346B1 (en) 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
JP2003522159A (ja) * 2000-02-08 2003-07-22 ザ ユニバーシティ オブ ヴァージニア パテント ファウンデーション 抗Ｃ３ｂ（ｉ）抗体を用いる感染の予防および治療のための方法
US20020006915A1 (en) 2000-02-15 2002-01-17 Mack Strong Vivian E. Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation
EP1275713A4 (fr) 2000-03-31 2004-06-30 Mochida Pharm Co Ltd Inhibiteur de liaison entre le recepteur de type toll et cd14
US20040092712A1 (en) 2000-03-31 2004-05-13 Shoji Furusako Tlr/cd14 binding inhibitor
BR0017338A (pt) 2000-09-29 2004-04-27 Neurogen Corp Composto, processo para preparar um composto, composição farmacêutica, e métodos para tratar um paciente, para inibir quimiotaxia celular promovida com c5a, para localizar receptores de c5a em um tecido, e para reduzir a gravidade ou frequência de uma ou mais sequelas inflamatórias de transplante de órgão
JPWO2002042333A1 (ja) 2000-11-22 2004-03-25 持田製薬株式会社 Ｃｄ１４／ｔｌｒ結合阻害作用を有する抗ｃｄ１４モノクローナル抗体
EP1345968A2 (fr) 2000-12-28 2003-09-24 Altus Biologics Inc. Cristaux d'anticorps entiers et fragments d'anticorps et methodes de fabrication et d'utilisation associees
US20030077576A1 (en) * 2001-03-20 2003-04-24 Joann Trial Use of monoclonal antibodies and functional assays for prediction of risk of opportunistic infection
US20030008822A1 (en) 2001-05-16 2003-01-09 Charles Dinarello Use of IL-18 inhibitors for the treatment or prevention of sepsis
BRPI0211953B8 (pt) * 2001-08-17 2021-05-25 Genentech Inc anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro
EP2422812A1 (fr) * 2003-02-21 2012-02-29 Genentech, Inc. Procédés pour prévenir et traiter des lésions tissulaires associées à une lésion de reperfusion d'ischémie

Also Published As

Publication number Publication date
EP2266606A1 (fr) 2010-12-29
ES2387275T3 (es) 2012-09-19
CA2524534A1 (fr) 2004-12-02
JP4768620B2 (ja) 2011-09-07
EP1628530B1 (fr) 2012-06-06
CA2524534C (fr) 2012-12-11
MXPA05011886A (es) 2006-02-17
JP2006528981A (ja) 2006-12-28
CN1787741B (zh) 2011-08-17
AU2010249190A1 (en) 2011-01-06
EP1628530B8 (fr) 2012-08-01
CN1787741A (zh) 2006-06-14
ES2522525T3 (es) 2014-11-14
EP1628530A4 (fr) 2007-08-29
EP2266606B1 (fr) 2014-09-10
US8329169B2 (en) 2012-12-11
US20070274989A1 (en) 2007-11-29
AU2004241069B2 (en) 2010-09-09
DK1628530T3 (da) 2012-07-23
EP1628530A2 (fr) 2006-03-01
AU2010249190B2 (en) 2013-02-28
WO2004103294A3 (fr) 2005-05-26
JP2011105747A (ja) 2011-06-02
WO2004103294A2 (fr) 2004-12-02
CN102258784A (zh) 2011-11-30
AU2004241069A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
HK1152474A1 (en) Methods and compositions for the prevention and treatment of sepsis
EP1644021A4 (fr) Methodes et compositions pour le traitement de troubles gastro-intestinaux
ZA200704677B (en) Compositions and methods for the treatment of autism
IL181896A0 (en) Methods and compositions for the treatment of hyperlipidemia
EP1633718A4 (fr) Compositions et procedes d'inhibition du facteur de croissance transformant beta (tgf-$g(b))
EP1692085A4 (fr) Inhibition de recepteur fgfr3 et traitement de myelome multiple
EP1711197A4 (fr) Methodes et compositions pour la prevention et le traitement de maladies ou de troubles inflammatoires
AU2003290605A8 (en) Compositions and methods for the diagnosis and treatment of sepsis
IL174627A0 (en) Compositions and methods for treatment of burns
IL183709A0 (en) Compositions and methods for treating conditions of the nail unit
ZA200703087B (en) Methods and compositions for the treatment of hyperlipidemia
EP1537089A4 (fr) Composes, compositions et procedes
EP1720563A4 (fr) Procedes et compositions de traitement de l'inflammation
IL187405A0 (en) Methods and compositions for the treatment of pain
EP1651255A4 (fr) Compositions veterinaires topiques et methodes de traitement et de prevention d'infections
AU2003297573A8 (en) Compositions and methods for treating transplants
IL165839A0 (en) Compounds useful for the treatment of cancer compositions thereof and methods therewith
EP1670492A4 (fr) Cytokines de protection des tissus pour le traitement et la prevention des septicemies et de la formation d'adhesions
EP1812797A4 (fr) Compositions et methodes permettant de traiter et de prevenir des maladies hyperproliferatives
PL368035A1 (en) Compositions and methods for the treatment of cancer
GB0324523D0 (en) Compositions and methods of treatment
EP1755581A4 (fr) Methodes et compositions de traitement d'etats myocardiques
AU2003220026A1 (en) Methods and compositions for the treatment of ischemia
AU2002303552A8 (en) Methods and compositions for prevention of angioproliferation
AU2003240174A8 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200518